CHMP to remove 100 generic medicines from market

Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.

Photo: Russell Cheyne/Reuters/Ritzau Scanpix

It now appears that fraudulent clinical trials by Indian contract research organization (CRO) Synchron Research Service will have an impact on the European market for generic medicines.

The European Medicines Agency’s (EMA) expert committee, the CHMP, has encouraged the EU Commission to withdraw the marketing approvals for around 100 generic medicines due to the fact that supporting data came from Synchron.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs